- Home
- DSY vs IPHA Comparison
DSY vs IPHA Comparison
Compare DSY & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSY
- IPHA
- Stock Information
- Founded
- DSY 2020
- IPHA 1999
- Country
- DSY China
- IPHA France
- Employees
- DSY N/A
- IPHA N/A
- Industry
- DSY
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- DSY
- IPHA Health Care
- Exchange
- DSY Nasdaq
- IPHA Nasdaq
- Market Cap
- DSY 130.7M
- IPHA 148.3M
- IPO Year
- DSY N/A
- IPHA 2019
- Fundamental
- Price
- DSY $2.60
- IPHA $1.77
- Analyst Decision
- DSY
- IPHA Strong Buy
- Analyst Count
- DSY 0
- IPHA 1
- Target Price
- DSY N/A
- IPHA $11.50
- AVG Volume (30 Days)
- DSY 51.6K
- IPHA 42.3K
- Earning Date
- DSY 02-10-2025
- IPHA 09-12-2024
- Dividend Yield
- DSY N/A
- IPHA N/A
- EPS Growth
- DSY 120.37
- IPHA N/A
- EPS
- DSY 0.01
- IPHA N/A
- Revenue
- DSY $7,323,356.00
- IPHA $36,202,722.00
- Revenue This Year
- DSY N/A
- IPHA N/A
- Revenue Next Year
- DSY N/A
- IPHA $101.65
- P/E Ratio
- DSY $279.76
- IPHA N/A
- Revenue Growth
- DSY 16.37
- IPHA N/A
- 52 Week Low
- DSY $0.75
- IPHA $1.29
- 52 Week High
- DSY $13.47
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- DSY 43.40
- IPHA 47.27
- Support Level
- DSY $2.65
- IPHA $1.65
- Resistance Level
- DSY $3.64
- IPHA $1.87
- Average True Range (ATR)
- DSY 0.43
- IPHA 0.10
- MACD
- DSY -0.04
- IPHA -0.02
- Stochastic Oscillator
- DSY 14.80
- IPHA 50.70
About DSY Big Tree Cloud Holdings Limited Ordinary Shares
Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, and sales of personal care products and other consumer goods. In particular, it is focused on the development and production of feminine pads and other feminine hygiene products. Through its platform, the company focuses on high-quality product development, deep customer engagement, and efficient sales and marketing.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.